Showing 1281-1290 of 5062 results for "".
- FDA Clears Xstrahl’s Radiant Aura for NMSCshttps://practicaldermatology.com/news/fda-clears-radiant-aura-receives-us-food-and-drug-administration-fda-510k-clearance/2461871/The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Xstrahl’s Radiant Aura, an office-based radiation therapy for non-melanoma skin cancer (NMSC). “We developed Radiant Aura to deliver both electronic brachytherapy and superficial radiation therapy in
- EMA to Review UCB’s Bimekizumab for HShttps://practicaldermatology.com/news/ema-to-review-ucbs-bimekizumab-for-hs/2461869/The European Medicines Agency (EMA) will reviww UCB’s marketing authorization application for bimekizumab for the treatment of adults with moderate to severe hidradenitis suppurativa (HS). Bimekizumab is an IL-17A and IL-17F inhibitor. The safety and efficacy of bim
- EULAR Seeks to Classify Risk of PsA in PsO Patientshttps://practicaldermatology.com/news/eular-seeks-to-classify-risk-of-psa-in-pso-patients/2461867/New EULAR points-to-consider characterize the transition from skin to joint involvement in psoriatic disease. Overall, five overarching principles and 10 points-to-consider were formulated by a multidisciplinary task force of 30 members from 13 European countries. The principles ac
- People Who Use Skin-Lightening Products May Be in the Dark About Riskshttps://practicaldermatology.com/news/people-who-use-skin-lightening-products-may-be-in-the-dark-about-risks/2461862/Skin-lightening products can be dangerous, but users aren’t always aware of the risks, a new study finds. To conduct the study, researchers sent an anonymous 19-question survey to individuals with skin of color in the U.S. asking about their demographics, colorism attitudes, skin
- DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its Melanoma Testhttps://practicaldermatology.com/news/dermtech-adds-approximately-7-million-covered-lives-for-the-foundational-assay-of-its-melanoma-test/2461861/DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced a favorable coverage policy from Highmark Inc. (Highmark). Highmark and its Blue-branded affiliates provide health insurance to approximately 7 million members in Pennsylvania, We
- Exosome News: ExoCoBio Completes Acquisition of Benevhttps://practicaldermatology.com/news/exosome-news-exocobio-completes-acquisition-of-benev/2461855/ExoCoBio has acquired a majority ownership in BENEV, a global medical aesthetic company that produces growth factor-based skincare products. ExoCoBio produces exosome-based regenerative aesthetics and medicine products and currently holds 54 patents and 15 scientific publicati
- Regular Moisturizer Use May Reduce Signs of Aging Skin, Plus More Research from Estée Lauderhttps://practicaldermatology.com/news/regular-moisturizer-use-may-reduce-signs-of-aging-skin-on-the-face-skin-aging-plus-more-wcd-presented-research-from-estee-lauder/2461846/Regular use of moisturizer can mitigate skin aging, according to research presented by The Estée Lauder Companies Inc. at the 25th World Congress of Dermatology in Singapore. In an evaluator-blinded, randomized, 6-month longitudinal study of 160 women, a
- AD Pipeline Watch: Eblasakimab Monthly Dosing Shows Promise in Phase 2b AD Studyhttps://practicaldermatology.com/news/eblasakimab-monthly-dosing-shows-promise-in-phase-2b-ad-study/2461845/ASLAN Pharmaceuticals’ eblasakimab met the primary endpoint of percent change from baseline in the Eczema Area and Severity Index (EASI) score at week 16 versus placebo in adult patients with moderate-to-severe atopic dermatitis (AD), according to results from the Phase 2b dose-ra
- Biosimilar News: Another Humira Biosimilar Enters US Markethttps://practicaldermatology.com/news/biosimilar-news-another-humira-biosimilar-enters-us-market/2461835/Biocon Biologics Ltd’s HULIO (adalimumab-fkjp) injection, a biosimilar to Humira (adalimumab), is now available in the United States after five years of experience in Europe and two years in Canada. "The launch of HULIO, our biosim
- Biosimilar News: Coherus Launches Humira Biosimilar at $995 per Carton in U.S.https://practicaldermatology.com/news/biosimilar-news-coherus-launches-humira-biosimilar-at-995-per-carton-in-us/2461834/Coherus BioSciences, Inc’s YUSIMRY (adalimumab-aqvh) is now available for commercial sale in the United States at a list price of $995 per carton for two 40 mg/0.8 mL autoinjectors. This cost represents a discount of more than 85% to Humira (adalimumab), currently price